$SNDY Rocketing Higher On News

Solos Endoscopy, Inc

MacReport Media   "Press Releases"

Solos Endoscopy, Inc. (OTC PINK: SNDY)is pleased to announce thatthe CompanysMammoView(R)Breast EndoscopySystemcanaid ingivingwomenthe best prognosis for recovery bydetectingbreast cancerat an earlier stagethan conventional methods(http://www.solosendoscopy.com/ductoscope-sell-sheet-final.pdf).

Physicians using the MammoView(R)Breast Endoscopy System can detect cancerous cells at .25mm compared to 1cm using the average conventional screening methods. Micro endoscopic detection allows physicians to clearly see the boundary between healthy and abnormal tissue. As a result, the MammoView(R)canimprove the chances that breast cancer bedetectedat an early stage and treated successfully.

Solos Endoscopy believes that all women, not just the rich and famous, need to benefit from early detection of breast cancer. Womenfrom all walks of life need to know theiroptions for detecting and preventing breast cancer, short of a mastectomy. Breast cancer is the most common cancer among women in the world. Of the five million women expected to die from breast cancer in the next decade, 70 percent will live inunder developedcountries.

Too many womendiscover they have been diagnosed with"breast cancer"at a point when their options for treatment are limited. The importance of early detectiontotreatment is well-recognized for reducing women's chances of dying from breast cancer. Breast health awareness, is a given in this country, however, many insurance companies do notnormallycovermammary ductoscopyproceduresfor early detection.

It is well documented that early detection is crucial in the fight against breast cancer. The MammoView(R)System is designed to significantly reduce the detection time andI believe it is an essential tool for earlybreast cancer screeningand treatment,stated Bob Segersten, President of Solos Endoscopy, Inc.

The Solos MammoView(R)Breast Endoscopy System can help more womendetectearly signsof disease and thereby seek advice as to multiple treatment options that early detection canoffer. Experts at theBreast Health Global Initiative(http://portal.bhgi.org/Pages/Default.aspx)and elsewhere propose tiered guidelines for diagnosis and treatment based on what's suitable and affordable for a country or community.Solos Endoscopy supportsimplementing such guidelines nowand giving Women more options for the early screening and detection of breast cancer.

The Solos MammoView(R)Breast Endoscopy System employs advanced microendoscopes and optical technology which gives physicians sharp images of the milk ducts where the majority of breast cancer arises.Solos Endoscopy instruments are FDA approved. Upon Solos Endoscopys receipt of its ISO 13485 Certification, the Company will be able to place theCE Mark on its entire MammoView(R)instrument line which will allow the instrument line to be sold globally. Both Solos and Expert Resource believe the ISO 13485 Certification and CE Mark initiative will be completed within the next few months. The Company has posted its schedule on its website.

TheSolosMammoView(R)Breast Endoscopy System includesa Microendoscope, Introducer, Dilator Set, and Cytology Retrieval Kit. Solos Endoscopys New MammoView(R)Breast Endoscopy Brochure is available online atwww.solosendoscopy.com.

About Solos Endoscopy, Inc.:

Solos Endoscopy is celebrating its 25^thYear of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy todevelop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Additional information on its FDA approved products is available on the Company's website at:www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available atwww.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Investor Relations

(617) 360-9719

SOURCE:Solos Endoscopy, Inc.